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We, at Grünenthal, want to place the patient at the centre of our way of thinking and behavior.Our daily work, as well as all strategic measures and 
decisions, are always guided by this vision. This means we set 
patient priorities and health as our first corporate goal to ensure 
we have a better understanding of the patient’s needs so that we 
can develop our business accordingly. 
For us, to be patient-centric means: understanding and 
integrating the patients’ perspective and their unmet needs 
in our day-to-day activities and decision making. Identifying 
patients’ needs helps us to reflect how we, as a pharmaceutical 
company, can improve their situation with our daily work. 
This not only implies better treatment by e.g. providing better 
formulations, packaging and labeling, but also offering easy access 
to information on pain management.
In 2011 we decided to set up a patient ambassador program 
allowing us to stay in close contact with chronic pain patients. A 
patient ambassador at Grünenthal is either someone living with 
chronic pain or someone caring for a pain patient. In addition, 
these patient ambassadors share our objective: we all want to 
improve and change the lives of those suffering from chronic pain. 
Through the patient ambassador program these patients or 
their carers have shared their stories with us and through them we 
have gained an in-depth insight into their lives and learned a lot 
about the challenges chronic pain patients are facing in their day-
to-day life, their dreams and wishes.
The direct contact and integration of the ambassadors in our 
field of business also enable us to ask them for their open feedback 
PaTIEnT CEnTRICITy
ThE PaTIEnT aMBaSSaDoR PRoGRaM aT GRünEnThal
and consultancy on various topics. In the past, several colleagues 
and departments took the opportunity to invite ambassadors 
to workshops or discussion rounds to ask for their input on e.g. 
formulations, packaging, how they rate different side-effects, 
and feedback on educational material for patients. Additionally 
they have access to our internal social network. This means that 
every employee has the possibility of starting discussions with the 
patient ambassadors and vice versa. This ensures that there is a 
continuous dialogue between employees and patient ambassadors 
which is one reason why the ambassadors are really integrated in 
the Grünenthal culture.
Sometimes, they also participate in external events organized 
in co-operation with health insurances, patient organizations, 
physicians and physiotherapists to raise awareness for a 
multimodal pain therapy approach among the general public. 
On these occasions the ambassadors share their experience and 
encourage other patient living with chronic pain not to give 
up and to work actively with their healthcare teams to find a 
treatment plan that works for them.
The Grünenthal Group is an independent, family-owned, 
international research-based pharmaceutical company 
headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective 
is to become the most patient-centric company in the field of 
pain and thus to be a leader in therapy innovation. Grünenthal is 
one of the last remaining five research-oriented pharmaceutical 
companies with headquarters in Germany which sustainably 
invests in research and development.  
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Relvar Ellipta (fluticasone furoate/vilanterol) Abridged Prescribing 
Information
▼This medicinal product is subject to additional monitoring. This will allow 
quick identification of new safety information. Healthcare professionals are asked 
to report any suspected adverse reactions. See section 4.8 on SPC how to report 
adverse reactions.
Please refer to the full Summary of Product Characteristics before prescribing
Trade Name: RELVAR ELLIPTA. Active Ingredients: 92 micrograms or 
184  micrograms of fluticasone furoate and 22 micrograms of vilanterol 
(as trifenatate). Pharmaceutical Form: 92 micrograms/22 micrograms or 
184 micrograms/22 micrograms inhalation powder, pre-dispensed. Indications: The 
92 micrograms/22 micrograms dose: for the regular treatment of asthma in adults 
and adolescents aged 12 years and older where use of a combination medicinal 
product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate; and 
for the symptomatic treatment of adults with COPD with a FEV1<70% predicted 
normal (post-bronchodilator) with an exacerbation history despite regular 
bronchodilator therapy. The 184 micrograms/22 micrograms dose: for the regular 
treatment of asthma in adults and adolescents aged 12 years and older where 
use of a combination medicinal product (long-acting beta2-agonist and inhaled 
corticosteroid) is appropriate. Dosage and Method of Administration: For 
Athsma: One inhalation of Relvar Ellipta 92/22 micrograms or 184/22 micrograms 
once daily. Patients usually experience an improvement in lung function within 
15 minutes of inhaling Relvar Ellipta. However, the patient should be informed 
that regular daily usage is necessary to maintain control of asthma symptoms 
and that use should be continued even when asymptomatic. If symptoms arise in 
the period between doses, an inhaled, short-acting beta2-agonist should be taken 
for immediate relief. A starting dose of Relvar Ellipta 92/22 micrograms should be 
considered for adults and adolescents 12 years and over who require a low to mid 
dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If 
patients are inadequately controlled on Relvar Ellipta 92/22 micrograms, the dose 
can be increased to 184/22 micrograms, which may provide additional improvement 
in asthma control. For COPD: One inhalation of Relvar Ellipta 92/22 micrograms 
once daily. Relvar Ellipta 184/22 micrograms is not indicated for patients with 
COPD. Relvar Ellipta is for inhalation use only. It should be administered at the 
same time of the day, each day. Contraindications: Hypersensitivity to the active 
ingredient or excipients. Precautions for Use: Fluticasone furoate/vilanterol 
should not be used to treat acute asthma symptoms, for which a short-acting 
bronchodilator is required. Caution in severe cardiovascular disease, moderate-to-
severe hepatic impairment, pulmonary tuberculosis or in patients with chronic or 
untreated infections, history of diabetes mellitus and for paradoxical bronchospasm 
and pneumonia in patients with COPD. Drug Interactions: Beta-blockers, CYP3A4 
inhibitors, P-glycoprotein inhibitors and sympathomimetic medicinal products 
(refer to the full Summary of Product Characteristics for list of drugs). Fertility, 
Pregnancy and Lactation: Pregnancy: No adequate data available. Lactation: 
insufficient information available. Fertility: There is no data in humans. Animal 
studies indicate no effect on fertility. Effect on Ability to Drive or Use Machines: 
No or negligible influence. Undesirable Effects: Very common side effects include 
headache and nasopharyngitis (refer to the full Summary of Product Characteristics 
for complete list of undesirable effects). Overdose: There is no specific antidote. 
Treatment of overdose should consist of general supportive measures. Local 
Presentations: Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, 
pre-dispensed and Relvar Ellipta 184 micrograms/22 micrograms inhalation 
powder, pre-dispensed. Legal Category: POM. Marketing Authorisation 
Holder: Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, 
United Kingdom Marketing Authorisation Numbers: EU/1/13/886/001-6 DATE 
OF PREPARATION: December 2013.
In order to ensure that this product information reflects the most up-to-
date clinical and post-marketing surveillance data, please always refer to 
the latest Summary of Product Characteristics (SPC) which is available from 
GlaxoSmithKline (Malta) Ltd (Tel: +356 21238131).
*Patients’ current or previous maintenance inhalers: HandiHaler/ DISKUS/ MDI/ HFA (COPD); DISKUS/ MDI/ 
HFA (asthma).4
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4. Woepse M et al. Qualitative assessment of a two-strip dry powder inhaler (ELLIPTA™) for COPD and 
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For patients like Maria, every day is full on, so even small reminders of 
asthma can have an impact. So, when they’re uncontrolled on ICS alone, 
choose new Relvar Ellipta:
 The ﬁ rst ICS/LABA combination to deliver continuous 24-hour efﬁ cacy2 
 In a practical, once-daily dose1
 Delivered in an easy to use device that patients prefer to their
current inhaler3,4*
REPORTING ADVERSE EVENTS (AEs): 
Malta & Gibraltar: If you become aware of any AEs, medication errors 
and/or use during pregnancy in association with GSK products, please 
report the event promptly to: GSK (Malta) Limited, 1, De la Cruz Avenue, 
Qormi QRM 2458, Malta (Tel: +356 21238131). 
Malta: alternatively, any suspected AEs and medication errors can also 
be reported via the national Adverse Drug Reactions (ADRs) reporting 
system: 
Report forms can be downloaded from www.medicinesauthority.gov.mt/
adrportal and posted to the Malta Medicines Authority, Post-licensing 
Directorate, 203, Level 3, Rue D’Argens, Gżira GŻR 1368, MALTA, or sent by 
email to postlicensing.medicinesauthority@gov.mt
Gibraltar: alternatively, any suspected AEs and medication errors 
can also be reported via the UK regulatory authority (MHRA): 
https://yellowcard.mhra.gov.uk/
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